Copyright
©The Author(s) 2015.
World J Orthop. Jan 18, 2015; 6(1): 62-76
Published online Jan 18, 2015. doi: 10.5312/wjo.v6.i1.62
Published online Jan 18, 2015. doi: 10.5312/wjo.v6.i1.62
Table 1 Prevalence of previous cardiovascular events in patients with and without diabetic foot
| Pts with diabetic foot (n = 102) < | Pts without diabetic foot (n = 123) | P | |
| CAD (%) | 33 (32.3) | 24 (19.5) | 0.0043 |
| TIA (%) | 15 (14.7) | 9 (7.3) | < 0.0001 |
| Stroke (%) | 18 (17.6) | 11 (8.9) | < 0.05 |
| Stroke toast subtypes | |||
| LAAS | 6 (33.3) | 5 (45.4) | |
| Lacunar | 12 (66.6) | 6 (54.5) | |
| CEI | 0 | 0 | |
| Diabetic retinopathy (%) | 55 (53.9) | 47 (38.2) | < 0.0001 |
| Renal failure (%) | 6 (5.8) | 7 (5.6) | NS |
Table 2 Cox regression analysis of demographic and clinical variables associated with cardiovascular morbidity n (%)
| Pts with diabeticfoot(n = 102) | Pts without diabetic foot(n = 123) | P | |
| CAD | 12 (11.7) | 7 (5.6) | < 0.005 |
| Angina | 4 (3.9) | 3 (2.4) | < 0.005 |
| Myocardialinfarction | 8 (7.8) | 4 (3.5) | < 0.001 |
| TIA | 6 (5.8) | 4 (3.2) | < 0.0001 |
| Stroke | 7 (6.8) | 5 (4.0) | < 0.005 |
| Renal failure | 4 (3.9) | 5 (4) | NS |
| Deaths | 14 (13.7) | 10 (8.1) | < 0.005 |
| Cardiovascular cause | 13 (12.7) | 9 (7.3) | |
| AMI | (3.9) | 1 (0.81) | NS |
| Stroke | 3 (2.9) | 2 (1.6) | |
| CHF | 3 (2.9) | 3 (2.4) | |
| Other vascular cause | 3 (2.9) | 3 (2.4) | |
| Other cause | 1 (0.9) | 1 (0.81) |
Table 3 Previous cerebro-vascular events in patients with and without diabetic foot
| Diabetic foot(n = 102) | No diabetic foot (n = 123) | P | |
| TIA | 15 (14.7) | 9 (7.3) | < 0.0001 |
| Ischemic stroke | 18 (17.6) | 11.8 (8.9) | < 0.0001 |
| Stroke toast subtype | |||
| LAAS | 6 (33.3) | 5 (45.4) | < 0005 |
| LAC | 12 (66.6) | 6 (54.5) | < 0.005 |
| CEI | 0 | 0 | |
Table 4 Incidence of stroke at follow-up in subjects with and without diabetic foot
| Diabetic foot(n = 102) | No diabetic foot(n = 123) | P | |
| TIA | 6 (5.8) | 4 (3.2) | < 0.0001 |
| Ischemicstroke | 7 (6.8) | 5 (4.0) | < 0.005 |
| LAAS | 4 | 3 | < 0.005 |
| LAC | 3 | 2 | < 0.005 |
| CEI | 0 | 0 | NS |
Table 5 General and demographic variables in cases and controls n (%)
| Pts with diabeticfoot | Pts without diabetic foot | P | |
| n | 34 | 37 | 0.75 |
| Age | 66.7 ± 8.5 | 66.9 ± 7.9 | 0.027 |
| Sex male | 16 (47.1) | 15 (41.7) | 0.41 |
| Diabetes duration | |||
| < 10 yr | 7 (20.6) | 21 (58.3) | 0.027 |
| = 10 yr | 8 (23.5) | 11 (30.6) | 0.045 |
| = 20 yr | 19 (55.9) | 4 (11.1) | < 0.001 |
| Treatment | |||
| Diet | 4 (11.8 ) | 3 ( 8.3) | 0.65 |
| Oral antidiabetics | 3 (8.8 ) | 10 (27.8) | < 0.001 |
| Mixed | 6 (17.5) | 13 (36.1) | < 0.001 |
| Insulin | 21 (61.8 ) | 10 (27.8) | < 0.001 |
| Smoking | 7 (20.6) | 9 (25) | 0.71 |
| Hypertension | 20 (58.8) | 25 (69.4) | 0.041 |
| Dyslipidaemia | 14 (41.2) | 16 (44.4) | 0.35 |
| Obesity | 19 (55.9) | 13 (36.1) | 0.021 |
| Chronic renal failure | 15 (44.1) | 13 (36.1) | 0.064 |
| Mycroalbuminuria | 22 (64.7) | 6 (14.7) | < 0.001 |
| Retinopathty | 19 (55.9) | 36 (100) | < 0.001 |
| PAD | 10 (29.41) | 9 (25) | 0.54 |
| CAD | 17 ( 50) | 7 (19.4) | < 0.001 |
| TIA/Stroke | 14 (41.17) | 6 (16.66) | 0.021 |
| Other district atherosclerosis | 28 (82.35 | 21 (58.33) | < 0.001 |
| Artropathy | 11 (32.4%) | 2 (5.6) | < 0.001 |
| Neuropathy | 25 (73.52) | 14 (38.88) | < 0.001 |
| Diabeticfootgrade | |||
| Grade 0 | 1 (2.9) | ||
| Grade 1 | 6 (17.6) | ||
| Grade 2 | 8 (23.5) | ||
| Grade 3 | 10 (29.4) | ||
| Grade4 | 4 (11.8) | ||
| Grade 5 | 1 (2.9) | ||
| Grade 6 | 4 (11.8) | ||
Table 6 Laboratory variables in cases and controls
| Diabetic foot patients | Diabetics without foot complications | P | |
| HbA1c | 8 (7.28-9.40) | 6.85 (6.10-8.00) | 0.018 |
| CRP | 4 (2.25-5.15 ) | 2.25 (1.90-3.08) | 0.041 |
| Total cholesterol (mg/dL) | 215.50 (166.50-243.00) | 204.00 (185.50-210.00) | 0.054 |
| LDL cholesterol (mg/dL) | 121.70 (98.75-148.75) | 104.50 (78.00-123.00) | 0.032 |
| Tryglicerids (mg/dL) | 160.50 (119.50-209.25) | 180.50 (144.50-199.00) | 0.012 |
| Globuli bianchi | 12.675 (10775.00-14140.00 ) | 10.700 (8850.00-12027.50) | 0.032 |
| Adiponectin (μg/mL) | 7.1450 (4.47-12.17) | 8.480 (5.15-12.87) | 0.022 |
| Resistin (ng/mL) | 5.160 (2.96-6.29) | 3.290 (2.37-6.5) | 0.021 |
| IL-6 (pg/mL) | 3.21 (1.23-5.34) | 2.13 (1.24-3.97 ) | 0.033 |
Table 7 Correlations of interleukin-1β, adiponectinresistin with clinical and laboratory variables in subjects with diabetic foot
| Variable | Adipenectin | Resistin | IL-6 | ||
| R | P values | R | P values | ||
| Diabetes duration | 0.36 (s) | < 0.001 (s) | 0.09 | 0.37 | |
| Smoking | 0.35 (s) | < 0.001 (s) | 0.10 | 0.22 | |
| Hypertension | 0.27 (s) | < 0.05 (s) | 0.12 | 0.35 | |
| Dyslipidaemia | 0.42 (s) | < 0.001 (s) | 0.14 | 0.15 | |
| Obesity | 0.13 | 0.42 | 0.12 | 0.22 | |
| Chronicrenalfailure | 0.11 | 0.56 | 0.12 | 0.35 | |
| Mycroalbuminuria | 0.08 | 0.37 | 0.08 | 0.37 | |
| Retinopathty | 0.10 | 0. 7 | 0.10 | 0. 7 | |
| AOPC | 0.11 | 0.81 | 0.10 | 0.77 | |
| CHD | 0.46 | < 0.001 (s) | 0.38 (s) | < 0.0001 (s) | |
| TIA/stroke | 0.12 | 0.42 | 0.13 | 0.32 | |
| Other district atherosclerosis | 0.15 (s) | 0.42 (s) | 0.14 (s) | 0.36 (s) | |
Table 8 Diabetic foot infection classification schemes: Infectious Diseases Society of America Infectious Diseases
| Clinical description | Infectious Diseases Society of America |
| Wound without purulence or any manifestations of inflammation | Uninfected |
| ≥ 2 Manifestations of inflammation (purulence or erythema, pain, tenderness, warmth, or induration); anyc ellulitis or erythemaextends 52 cm around ulcer, and infection is limited to skin or superficial subcutaneous stissues; no localcomplications or systemic illness | Mild |
| Infection in a patientwho is systemicallywell and metabolicall ystable buthas 2 cm; lymphangitis; spread beneath fascia; deeptissue abscess; gangrene; muscle, tendon, joint, or bone involvement | Moderate |
| Infection in a patient with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, hyperglycemia, or azotemia) | Severe |
- Citation: Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop 2015; 6(1): 62-76
- URL: https://www.wjgnet.com/2218-5836/full/v6/i1/62.htm
- DOI: https://dx.doi.org/10.5312/wjo.v6.i1.62
